Program
mirikizumab
Also written as “Mirikizumab”, “LY3074828” and “Mirikizumab IV”.
Its studies are mostly in Colitis, Ulcerative · Psoriasis · Crohn Disease · Breast Feeding, led by 2 companies.
Drug pageMirikizumab: every studyAll 44 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 356 open or running | phase 4since May 21, 2026 | Sep 18, 2013 | Feb 2027phase 1 · NCT07446101 |
| Rubix LSits history only | 11 open or running | phase 4since Jul 1, 2025 | Jul 1, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 22 earlier studies, Sep 18, 2013 to Jan 15, 2020.
- Jun 9, 2017Named mirikizumabINNProposed as its International Nonproprietary Name in WHO's List 117 · before, LY3074828
- Jul 10, 2020Phase 3 study in Colitis, UlcerativeEli Lilly · NCT04469062
- Sep 10, 2020Phase 1 study in HealthyEli Lilly · NCT04548219 · 60 enrolled · United States
- Oct 28, 2020Phase 1 study in HealthyEli Lilly · NCT04607733 · 240 enrolled · United States
- Apr 12, 2021Phase 3 study in Colitis, UlcerativeEli Lilly · NCT04844606 · 150 planned · United States, Austria, Belgium and more
- Oct 1, 2021Phase 1 study in HealthyEli Lilly · NCT05069896 · 237 enrolled · United States
- Aug 19, 2022Phase 3 study in Crohn DiseaseEli Lilly · NCT05509777 · 90 planned · United States, Austria, Belgium and more
- Aug 24, 2022Phase 1 study in HealthyEli Lilly · NCT05515601 · 396 enrolled · United States
- Dec 1, 2022Phase 1 study in HealthyEli Lilly · NCT05644353 · 450 enrolled · United States
- Feb 8, 2023Phase 3 study in Colitis, UlcerativeEli Lilly · NCT05767021 · 172 enrolled · United States, Belgium, Czechia and more
- Mar 13, 2023Phase 3 study in Colitis, UlcerativeEli Lilly · NCT05784246 · 63 enrolled · United States, Belgium, Canada and more
- Jun 21, 2024Phase 1 study in HealthyEli Lilly · NCT06475729 · 498 enrolled · United States
- Jul 1, 2025Rubix LS’ first study: phase 4 study in Crohn DiseaseNew to Rubix LSRubix LS · NCT07059130 · 150 planned · United States
- Feb 26, 2026Phase 1 study in HealthyEli Lilly · NCT07446101 · 450 planned · United States
- May 21, 2026Phase 4 study in Breast FeedingEli Lilly · NCT07612267 · 14 planned · United States, Canada, Denmark and more
Ahead
- Feb 2027Primary completion: phase 1 study in HealthyEli Lilly · NCT07446101
- Dec 2027Primary completion: phase 3 study in Crohn DiseaseEli Lilly · NCT05509777
- Sep 2028Primary completion: phase 4 study in Breast FeedingEli Lilly · NCT07612267
- Dec 2030Primary completion: phase 3 study in Colitis, UlcerativeEli Lilly · NCT04844606
TargetBeta
“Interleukin-23 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| risankizumabrule | AbbVie | phase 4 | 68 |
| guselkumabrule | Johnson & Johnson | phase 4 | 60 |
Studies
All 36 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07612267Breast Feeding · United States, Canada, Denmark and more | 4 | Recruiting | Eli Lilly | Sep 2028 | 14 |
| NCT07446101Healthy · United States | 1 | Recruiting | Eli Lilly | Feb 2027 | 450 |
| NCT07059130Crohn Disease · United States | 4 | Not yet recruiting | Rubix LS | Jan 1, 2026 | 150 |
| NCT06475729Healthy · United States | 1 | Completed | Eli Lilly | Dec 27, 2024 | 498 |
| NCT05784246Colitis, Ulcerative · United States, Belgium, Canada and more | 3 | Completed | Eli Lilly | May 1, 2026 | 63 |
| NCT05767021Colitis, Ulcerative · United States, Belgium, Czechia and more | 3 | Completed | Eli Lilly | Aug 9, 2024 | 172 |
| NCT05644353Healthy · United States | 1 | Completed | Eli Lilly | May 25, 2023 | 450 |
| NCT05515601Healthy · United States | 1 | Completed | Eli Lilly | Feb 20, 2023 | 396 |
| NCT05509777Crohn Disease · United States, Austria, Belgium and more | 3 | Recruiting | Eli Lilly | Dec 2027 | 90 |
| NCT05069896Healthy · United States | 1 | Completed | Eli Lilly | Jun 22, 2022 | 237 |
| NCT04844606Colitis, Ulcerative · United States, Austria, Belgium and more | 3 | Recruiting | Eli Lilly | Dec 2030 | 150 |
| NCT04607733Healthy · United States | 1 | Completed | Eli Lilly | May 17, 2021 | 240 |
| NCT04548219Healthy · United States | 1 | Completed | Eli Lilly | Jan 11, 2021 | 60 |
| NCT04469062Colitis, Ulcerative | 3 | Withdrawn | Eli Lilly | Mar 13, 2024 | 0 |
| NCT04232553Crohn Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | Eli Lilly | Nov 28, 2024 | 996 |
| NCT04137380Healthy · China | 1 | Completed | Eli Lilly | Dec 11, 2020 | 60 |
| NCT04004611Colitis, Ulcerative · United States, Canada, Israel and more | 2 | Completed | Eli Lilly | Mar 15, 2023 | 26 |
| NCT03926130Crohn Disease · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Aug 23, 2023 | 1,158 |
| NCT03718884Psoriasis · United States | 1 | Completed | Eli Lilly | Oct 28, 2019 | 29 |
| NCT03748940Healthy · United Kingdom | 1 | Completed | Eli Lilly | Jun 18, 2019 | 60 |
| NCT03662100Healthy · United States | 1 | Completed | Eli Lilly | Jan 25, 2019 | 66 |
| NCT03556202Psoriasis · United States, Argentina, Australia and more | 3 | Terminated | Eli Lilly | Feb 7, 2022 | 1,936 |
| NCT03535194Psoriasis · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Mar 5, 2020 | 1,484 |
| NCT03524092Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Nov 3, 2021 | 1,328 |
| NCT03519945Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Active, not recruiting | Eli Lilly | Mar 4, 2026 | 1,058 |
| NCT03518086Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Jan 21, 2021 | 1,281 |
| NCT03482011Psoriasis · United States, Germany, Japan and more | 3 | Completed | Eli Lilly | Mar 21, 2019 | 530 |
| NCT03456713Healthy · United States | 1 | Completed | Eli Lilly | Aug 13, 2018 | 72 |
| NCT03220126Healthy · United Kingdom | 1 | Completed | Eli Lilly | Feb 23, 2018 | 72 |
| NCT03188510Healthy · United States | 1 | Completed | Eli Lilly | Nov 27, 2017 | 54 |
| NCT03053622Healthy · United Kingdom | 1 | Completed | Eli Lilly | Apr 3, 2018 | 67 |
| NCT02899988Plaque Psoriasis · United States, Canada, Germany and more | 2 | Completed | Eli Lilly | Jun 19, 2017 | 205 |
| NCT02891226Crohn Disease · United States, Australia, Belgium and more | 2 | Completed | Eli Lilly | Dec 11, 2018 | 191 |
| NCT02589665Colitis, Ulcerative · United States, Australia, Belgium and more | 2 | Completed | Eli Lilly | Dec 19, 2017 | 249 |
| NCT02568423Healthy · United States | 1 | Completed | Eli Lilly | Jul 16, 2018 | 51 |
| NCT01947933Psoriasis · Canada | 1 | Completed | Eli Lilly | Feb 2015 | 45 |
How it is read
Names in the registry
- “Mirikizumab”, 24 entries
- “LY3074828”, 6 entries
- “Mirikizumab IV”, 3 entries
- “Mirikizumab SC”, 3 entries
- “Mirikizumab - SC”, 3 entries
Conditions, from the studies’ own filings
- Colitis, Ulcerative, 9 studies
- Psoriasis, 6 studies
- Crohn Disease, 5 studies
- Breast Feeding, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.